MRI pharmaceutical developer Epix Medical of Cambridge, MA, has received U.S. Patent No. 6,676,929.
The patent grants composition-of-matter claims for the chemical structure of the firm’s lead compound, MS-325 (gadofosveset), a contrast agent designed specifically for vascular imaging with magnetic resonance angiography (MRA).
The company recently submitted a new drug application with the U.S. Food and Drug Administrations for the agent, which was co-developed by Epix and Schering of Berlin.
By AuntMinnie.com staff writersJanuary 13, 2004
Related Reading
Epix submits MR contrast agent for FDA approval, December 16, 2003
Epix COO resigns, November 11, 2003
Epix continues to build revenues, trim losses in Q3, October 24, 2003
Epix to present phase III results, September 15, 2003
Epix exercises overallotment option, August 27, 2003
Copyright © 2004 AuntMinnie.com
